Brought to you by 
Generex signals interest in infertility through LOI to buy MediTemp
27 Oct 2015
Executive Summary
Generex Biotechnology Corp. signed a letter of intent (LOI), indicating an interest in paying $5mm for a 51% stake in Israeli device firm MediTemp Ltd., which is developing a product to treat male infertility. The deal could also include royalties.
Deal Industry
- Medical Devices
Deal Status
- Preliminary
Deal Type
-
Acquisition
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Generex signals interest in infertility through LOI to buy MediTemp
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice